Transient Acantholytic Dermatosis Medication
- Author: Edward J Zabawski Jr, DO; Chief Editor: Dirk M Elston, MD more...
Medication Summary
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
Retinoids
Class Summary
These agents decrease the cohesiveness of abnormal hyperproliferative keratinocytes, and they may reduce the potential for malignant degeneration. They also affect keratinocyte differentiation.
Isotretinoin (Accutane)
Oral agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of the naturally occurring tretinoin (trans- retinoic acid). Both agents are structurally related to vitamin A.
A US Food and Drug Administration–mandated registry is now in place for all individuals prescribing, dispensing, or taking isotretinoin. For more information on this registry, see iPLEDGE. This registry aims to further decrease the risk of pregnancy and other unwanted and potentially dangerous adverse effects during a course of isotretinoin therapy.
Corticosteroids
Class Summary
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
Prednisone (Deltasone, Sterapred, Orasone)
Immunosuppressant for treatment of autoimmune disorders; may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
Antimetabolites
Class Summary
These agents regulate cell growth and differentiation.
Methotrexate (Folex PFS, Rheumatrex)
Antimetabolite that inhibits DNA synthesis and cell reproduction in malignant cells. Unknown mechanism of action in treatment of inflammatory reactions; may affect immune function. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness).
Grover RW. Transient acantholytic dermatosis. Arch Dermatol. Apr 1970;101(4):426-34. [Medline].
Streit M, Paredes BE, Braathen LR, Brand CU. [Transitory acantholytic dermatosis (Grover disease). An analysis of the clinical spectrum based on 21 histologically assessed cases]. Hautarzt. Apr 2000;51(4):244-9. [Medline].
Scheinfeld N, Mones J. Seasonal variation of transient acantholytic dyskeratosis (Grover's disease). J Am Acad Dermatol. Aug 2006;55(2):263-8. [Medline].
Fujita Y, Sato-Matsumura KC, Ohnishi K. Transient acantholytic dermatosis associated with B symptoms of follicular lymphoma. Clin Exp Dermatol. Nov 2007;32(6):752-4. [Medline].
Ishibashi M, Nagasaka T, Chen KR. Remission of transient acantholytic dermatosis after the treatment with rituximab for follicular lymphoma. Clin Exp Dermatol. Mar 2008;33(2):206-7. [Medline].
Kanzaki T, Hashimoto K. Transient acantholytic dermatosis with involvement of oral mucosa. J Cutan Pathol. Feb 1978;5(1):23-30. [Medline].
Fantini F, Kovacs E, Scarabello A. Unilateral transient acantholytic dermatosis (Grover's disease) along Blaschko lines. J Am Acad Dermatol. Aug 2002;47(2):319-20. [Medline].
Liss WA, Norins AL. Zosteriform transient acantholytic dermatosis. J Am Acad Dermatol. Nov 1993;29(5 Pt 1):797-8. [Medline].
Gilchrist H, Jackson S, Morse L, Nicotri T, Nesbitt LT. Galli-Galli disease: A case report with review of the literature. J Am Acad Dermatol. Feb 2008;58(2):299-302. [Medline].
Fernández-Figueras MT, Puig L, Cannata P, Cuatrecases M, Quer A, Ferrándiz C, et al. Grover disease: a reappraisal of histopathological diagnostic criteria in 120 cases. Am J Dermatopathol. Aug 2010;32(6):541-9. [Medline].
Helfman RJ. Grover's disease treated with isotretinoin. Report of four cases. J Am Acad Dermatol. Jun 1985;12(6):981-4. [Medline].
Miljkovic J, Marko PB. Grover's disease: successful treatment with acitretin and calcipotriol. Wien Klin Wochenschr. 2004;116 Suppl 2:81-3. [Medline].
Breuckmann F, Appelhans C, Altmeyer P, Kreuter A. Medium-dose ultraviolet A1 phototherapy in transient acantholytic dermatosis (Grover's disease). J Am Acad Dermatol. Jan 2005;52(1):169-70. [Medline].

